Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bertilimumab - Immune Pharmaceuticals

Next Previous
X
Search
Drug Profile

Bertilimumab - Immune Pharmaceuticals

Alternative Names: Anti-eotaxin human monoclonal antibody; CAT-213; iCo-008

Latest Information Update: 28 Nov 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cambridge Antibody Technology
  • Developer AstraZeneca; iCo Therapeutics; Immune Pharmaceuticals Inc
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antineoplastics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Chemokine CCL11 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bullous pemphigoid
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Allergic conjunctivitis; Allergic rhinitis; Bullous pemphigoid; Crohn's disease; Ulcerative colitis
  • No development reported Asthma; Atopic dermatitis; Non-alcoholic steatohepatitis; Wet age-related macular degeneration
  • Discontinued Ovarian cancer

Most Recent Events

  • 28 Nov 2021 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in Israel (PO)
  • 01 Oct 2019 Alexion to acquire anti-eotaxin-1 antibody from Immune Pharmaceuticals
  • 30 Jun 2019 Bertilimumab receives Fast Track designation for Bullous pemphigoid [IV,Infusion] (Newly diagnosed) in USA before June 2019

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top